Literature DB >> 36261664

Onychomycosis in underrepresented groups: an all of us database analysis.

Isabelle Moseley1, Sara D Ragi2, Samantha Ouellette3, Babar Rao4.   

Abstract

Few research studies evaluating the impact of dermatologic diseases in the United States (US) have adequately included underrepresented groups. All of Us (AoU) is an ongoing precision medicine-based research initiative by the National Institutes of Health (NIH) that facilitates research in populations traditionally underrepresented in biomedical research by prioritizing them for data collection. Our objective was to evaluate the burden of onychomycosis in underrepresented groups defined by the framework provided by AoU. The AoU Registered Tier dataset version 5 was used which includes data collected between May 30, 2017 and April 1, 2021. We conducted a cross-sectional analysis linking survey and electronic health record (EHR) data to estimate the prevalence of onychomycosis in underrepresented groups defined by race, ethnicity, age (≥ 75 years), disability, sexual orientation/gender identity (LGBTQIA +), income (annual household income ≤ $35 000) and education (less than a high school degree). The latest All of Us data release includes 329,038 participants. Of these, 251,597 (76%) had EHR data and 13,874 had onychomycosis (overall prevalence, 5.5%; 95% CI, 5.4-5.6). Multivariate analyses adjusted by tinea pedis, diabetes mellitus, immune compromise, nail psoriasis, and insurance status, in addition to the aforementioned variables, revealed that, compared with White participants, Black and Hispanic participants had a higher adjusted odds of onychomycosis (OR, 1.29; 95% CI, 1.23-1.36 and OR, 1.24; 95% CI, 1.17-1.31, respectively). Higher adjusted odds of onychomycosis were also observed in underrepresented groups. Our findings suggest a disproportionately high burden of onychomycosis in underrepresented groups, although further studies are needed to replicate our findings and address this disparity.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Fungal infection; General dermatology; Medical dermatology; Nail; Onychomycosis

Year:  2022        PMID: 36261664     DOI: 10.1007/s00403-022-02413-4

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.033


  6 in total

1.  Putting onychomycosis under the microscope.

Authors:  Tiffany T Mayo; Wendy Cantrell
Journal:  Nurse Pract       Date:  2014-05-12

2.  Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients.

Authors:  A K Gupta; H C Jain; C W Lynde; P Macdonald; E A Cooper; R C Summerbell
Journal:  J Am Acad Dermatol       Date:  2000-08       Impact factor: 11.527

3.  Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada--a multicenter survey of 2001 patients.

Authors:  A K Gupta; H C Jain; C W Lynde; G N Watteel; R C Summerbell
Journal:  Int J Dermatol       Date:  1997-10       Impact factor: 2.736

Review 4.  Cutaneous reaction to drugs used for erectile dysfunction: case report and review of the literature.

Authors:  Renee A Beach; Frank Murphy; Ronald B Vender
Journal:  J Cutan Med Surg       Date:  2006 May-Jun       Impact factor: 2.092

5.  Cutaneous fungal infections in the United States: Analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995-2004.

Authors:  Anil A Panackal; Elkan F Halpern; Alice J Watson
Journal:  Int J Dermatol       Date:  2009-07       Impact factor: 2.736

Review 6.  Onychomycosis--epidemiology, diagnosis and management.

Authors:  R Kaur; B Kashyap; P Bhalla
Journal:  Indian J Med Microbiol       Date:  2008 Apr-Jun       Impact factor: 0.985

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.